Last reviewed · How we verify

Grazoprevir plus Elbasvir

Kyushu University · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

Grazoprevir plus Elbasvir is a Small molecule drug developed by Kyushu University. It is currently FDA-approved.

Grazoprevir plus Elbasvir is a small molecule combination treatment used to study various conditions, including Hepatitis C, HIV, and Cardiovascular Diseases, as per ClinicalTrials.gov. The combination is available in a fixed-dose form, specifically Grazoprevir 100 mg/Elbasvir 50 mg tablets, as per ClinicalTrials.gov.

At a glance

Generic nameGrazoprevir plus Elbasvir
SponsorKyushu University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Grazoprevir plus Elbasvir

What is Grazoprevir plus Elbasvir?

Grazoprevir plus Elbasvir is a Small molecule drug developed by Kyushu University.

Who makes Grazoprevir plus Elbasvir?

Grazoprevir plus Elbasvir is developed and marketed by Kyushu University (see full Kyushu University pipeline at /company/kyushu-university).

What development phase is Grazoprevir plus Elbasvir in?

Grazoprevir plus Elbasvir is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing